Table 1 Participant characteristics at baseline assessment

N (females)

8 (5)

8 (5)

8 (6)

8 (6)

Anti-TNFα agent (Infliximab/Etanercept/Adalimumab)

5/3/0

4/3/1

6/2/0

5/3/0

Smokers (current; ex)

3 (1; 2)

4 (1; 3)

3 (2; 1)

4 (2; 2)

Age (years)

60.8

62.2

58.6

60.8

(6.9)

(7.8)

(6.7)

(8.0)

Height (cm)

165.9

167

165.4

165.2

(10.6)

(12.2)

(11.9)

(9.4)

Weight (kg)

60.3

61.6

88.9

89.8

(6.4)

(7.2)

(10.1)

(9.6)

BMI (kg/m ² )

21.8

22.1

32.3

32.8

(2.4)

(2.2)

(3.0)

(3.1)

HOMA

2.9

2.2*

3.1

2.1^#

(0.7)

(0.4)

(0.5)

(0.8)

QUICKI

0.29

0.36*

0.30

0.37^#

(0.02)

(0.03)

(0.03)

(0.01)

HAQ

1.6

1.8

1.7

2.0

(0.3)

(0.2)

(0.4)

(0.5)

DAS

5.7

5.9

6.2

6.1

(0.7)

(0.5)

(1.0)

(0.6)

ESR (mm/h)

31

38

35

43

(7.5)

(10)

(9.5)

(12.5)

CRP (mg/L)

29

32.5

31.4

34.2

(6.4)

(8.2)

(8.8)

(7.4)

Disease Duration

9.1

8.6

8

10.2

(years)

(2.5)

(2.3)

(3.6)

(4.7)